Formulary Chapter 5: Infections - Full Chapter
|
05.04.01 |
Treatment of malaria |
|
|
05.04.01 |
Falciparum malaria (treatment) |
|
|
05.04.01 |
Benign malarias (treatment) |
|
|
05.04.01 |
Prophylaxis against malaria |
|
|
05.04.01 |
Specific recommendations |
|
|
05.04.01 |
Artemether with lumefabtrine |
|
|
Artemether with lumefantrine (Riamet®)

|
Non Formulary
|
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
"Amber 1" - These are medicines that require significant monitoring and the decision to treat with an AMBER medicine should be made by specialists only |

|
"Amber 2" - These are medicines that require little or no monitoring by the GP, but should only be prescribed in general practice after they have been recommended following specialist referral. |

|
"Red" - Secondary care only |

|
"Double Red" - NOT recommended for prescribing in either primary or secondary care |

|
Traffic light status to be confirmed |

|
May be prescribed in primary and secondary care |
|
|